chufangao/CTO huggingface dataset:
Clinical trial NCT02661971: FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Official title: Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO
Acronym: RAMSES/FLOT7
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2021-12-31
Completion date: 2022-06-20
Plan to share individual participant data: NO
IPD sharing description: No IPD will be shared.
Clinical trial NCT01929811: NeoMET Study in Neoadjuvant Treatment of Breast Cancer
Official title: Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial
Acronym: NeoMET
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow enrollment.
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-10-31
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT05219370: Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD
Official title: Treatment With Cannabis Oil Containing Canabidiol (CBD) Tetrahydrocannabinol (THC), Cannabidivarin (CBDV) or Cannabigerol (CBG) vs. Placebo of Persons Diagnosed With ADHD After Failure of Conventional Treatment
Sponsor: Brlev Agricultural Crops Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulties in enrollment
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-07-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: YES
IPD sharing description: Study protocol and Statistical Analysis Plan to be shared
IPD time frame: during all the trial
IPD access criteria: interested colleagues
Clinical trial NCT04343235: Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
Official title: Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial
Sponsor: Wright State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Challenges with enrollment; primary investigator left the institution
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-01
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
IPD sharing description: Data will be shared on a case by case basis
Clinical trial NCT04126278: Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
Official title: Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection: A Randomized Controlled Double-Blind Study
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment difficulty.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2022-08-12
Completion date: 2022-08-23
Baseline population: No patients enrolled in the Barbotage Injection arm (see participant flow).
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: Upon reasonable request. Requests should be directed to Mehul.Shah@nyulangone.org. To gain access, data requester will need to sign a data access agreement.
Clinical trial NCT05405686: Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders
Official title: Endometrial Gene Expression Profiles During Ovarian Stimulation With Recombinant FSH With or Without the Addition of Recombinant LH in Genuine Poor Responders
Sponsor: CRG UZ Brussel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: withdrawn due to practical reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-01
Primary completion date: 2023-08-01
Completion date: 2024-08-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03284307: UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study
Official title: UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study
Acronym: UN-CONSCIOUS
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-10
Primary completion date: 2020-03-12
Completion date: 2020-03-12
Baseline population: All participants who completed a sleep and/or sedation visit.
Limitations and caveats: The fourth study drug was changed from sevoflurane to midazolam in November of 2019 due to concerns about conducting experiments in patients inhaling a volatile anesthetic through a face mask and the difficulty we would have with communicating with patients. The cessation of human subjects research due to the COVID-19 pandemic and amended institutional guidelines for conducting in-person research caused far fewer participants to be recruited than was planned.
Clinical trial NCT05618691: A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Official title: A Double-blinded, Randomized, Placebo-controlled Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Sponsor: Genfleet Therapeutics (Shanghai) Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study was terminated by sponsor for reasons of adjusted clinical development strategy.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-12-01
Primary completion date: 2023-12-31
Completion date: 2024-05-31
Plan to share individual participant data: NO
Clinical trial NCT03807856: Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Official title: Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Difficult recruitment
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-24
Primary completion date: 2020-07-23
Completion date: 2020-07-23
Plan to share individual participant data: NO
Clinical trial NCT02504216: Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Official title: An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Acronym: VOYAGER PAD
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 6564.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-18
Primary completion date: 2019-11-27
Completion date: 2020-01-09
Clinical trial NCT04173494: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Official title: A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
Sponsor: Sierra Oncology LLC - a GSK company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 195.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-07
Primary completion date: 2021-12-03
Completion date: 2022-12-29
Baseline population: Baseline characteristics were measured in the Intention-To-Treat (ITT) Analysis Set, which included all randomized participants.
Plan to share individual participant data: NO
Clinical trial NCT03945604: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
Official title: A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-04
Primary completion date: 2021-02-09
Completion date: 2021-02-09
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05269667: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Official title: SAkuraBonsai: Clinical, Imaging And Biomarker Open-Label Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Acronym: SAkuraBonsai
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study has proved infeasible to recruit in sufficient numbers. There are insufficient eligible patients presenting to sites.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-02
Primary completion date: 2023-10-26
Completion date: 2023-10-26
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT04674761: Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Official title: A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Acronym: ASSERT
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-19
Primary completion date: 2022-09-09
Completion date: 2022-09-09
Clinical trial NCT04989218: Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
Official title: An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC)
Acronym: ICC
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow accrual and study sponsor decision.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-30
Primary completion date: 2024-03-20
Completion date: 2024-05-01
Plan to share individual participant data: NO
IPD sharing description: To be determined
Clinical trial NCT04455815: A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
Official title: A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.
Acronym: SPIKE-1
Sponsor: Cancer Research UK (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-23
Primary completion date: 2021-11-29
Completion date: 2022-03-03
Plan to share individual participant data: YES
IPD sharing description: Individual de-identified patient data will be shared with researchers whose proposed use of the data is approved by a review committee of the Sponsor.
IPD time frame: All requests made within 5 years from end-of-trial will be considered; requests made subsequently will be considered where possible.
IPD access criteria: When a request has been approved Cancer Research UK will provide access to the de-identified individual patient-level data and appropriate supporting information. A signed Data Sharing Agreement must be in place before accessing requested information. Requests should be submitted to drugdev@cancer.org.uk.
Clinical trial NCT03224819: Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Official title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Priortization of other Programs
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-07
Primary completion date: 2020-12-28
Completion date: 2020-12-28
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT03331640: A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
Official title: A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON)
Acronym: PANTHEON
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow recruitment
Enrollment: 67.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-02
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Clinical trial NCT03926611: This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
Official title: A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 311.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-06-06
Primary completion date: 2021-01-14
Completion date: 2021-04-15
Baseline population: Randomized Set included all randomized subjects, regardless of whether or not they actually received study medication. Subjects were analyzed according to the treatment assigned at randomization.
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03714152: A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B
Official title: A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Doses of ABI-H2158 in Healthy Volunteers; and the Multiple-Ascending Dose Pharmacokinetics and Pharmacodynamics in Patients With Chronic Hepatitis B Infection
Sponsor: Assembly Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-13
Primary completion date: 2020-11-23
Completion date: 2021-01-07
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01399372: Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Official title: Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-09-30
Primary completion date: 2020-03-19
Completion date: 2022-05-20
Baseline population: Eligible participants
Limitations and caveats: A planned interim efficacy analysis was performed after 42 events (death or progression). The final analysis was planned to occur after 67 events. The Data Monitoring Committee (DMC) recommended releasing the interim results for early reporting and these results are considered the final study results.
Clinical trial NCT05324852: AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine
Official title: AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine, a Randomized Non Inferiority Trial
Acronym: AGINASAL
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision:
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-04-09
Primary completion date: 2023-04-09
Completion date: 2024-04-23
Plan to share individual participant data: NO
Clinical trial NCT03549000: A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Official title: A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: After review of data which showed low likelihood of efficacy in these patients Novartis decided to terminate the trial early. Termination was not safety related
Enrollment: 127.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-07-18
Primary completion date: 2022-10-17
Completion date: 2022-10-17
Plan to share individual participant data: NO
Clinical trial NCT03237286: Intravenous Ketamine Plus Neurocognitive Training for Depression
Official title: Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 154.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-12-01
Primary completion date: 2022-10-18
Completion date: 2022-10-18
Plan to share individual participant data: YES
IPD sharing description: We will comply with all NIMH guidelines regarding data repository/sharing.
IPD time frame: We will comply with all NIMH guidelines regarding data repository/sharing.
Clinical trial NCT03468140: Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
Official title: A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Unable to recruit due to COVID 19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2023-04-30
Completion date: 2023-12-31
Clinical trial NCT03783078: Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Official title: A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First Line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-25
Primary completion date: 2022-02-15
Completion date: 2024-02-15
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04433988: Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Official title: Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Sponsor: Sadat City University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Institutional problems
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-13
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: YES
Clinical trial NCT04380519: Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
Official title: An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)
Sponsor: R-Pharm (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 372.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-23
Primary completion date: 2020-07-10
Completion date: 2020-07-24
Clinical trial NCT00254384: Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery
Official title: Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 1.0
Start date: 2005-10-05
Primary completion date: 2024-05-21
Completion date: 2024-05-21